Gilead Sciences (GILD) 104.76 $GILD
Final Glance: Biotechnology companies
AP - 6 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Gilead Sciences
at Investor's Business Daily - 59 mins ago
Gilead Sciences (GILD) shares rose 3.7% to 104.76, as FBR analyst Andrew Berens raised his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. Berens raised his estimate to $2.24 bil from $1.94 bil after examining Aug. prescription data...
AHF Joins National Coalition on Health Care's 'Campaign for Sustainable Rx Pricing'
Business Wire - 1 hr 31 mins ago
--The Bay Area drug company drew outrage--and Congressional scrutiny--by pricing its hepatitis C drug Sovaldi at $84,000 for a 12-week course of treatment--or $1,000 per pill. Pharmasset, the company that developed Sovaldi--and for which Gilead paid $11 billion cash--intended to price the drug at $36,000.
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 42 mins ago
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C
Marketwire Canada - 2 hrs 1 min ago
Hetero Group, today announced that it has obtained licensing rights to manufacture and market sofosbuvir and combination drug ledipasvir/sofosbuvir upon approval from Gilead Sciences Inc., USA for 90 countries. Under the said agreement, Hetero is entitled to manufacture and market sofosbuvir and ledipasvir/sofosbuvir in the territories of India, Asia Pacific, Sub-Saharan Africa and other Least Developed Countries. This will expand access of affordable medicines to patients who are infected with chronic hepatitis C in various developing countries. This licensing association marks a significant milestone in ensuring the medicines are accessible globally and thereby addressing the significant public health care issue.
AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 32 mins ago
AstraZeneca (AZN) has entered into an agreement with Eli Lilly and Company (LLY) for the development and commercialization of AZD3293.
Stocks Rise Ahead Of Fed, Led By Biotech, Chip Names
at Investor's Business Daily - 2 hrs 51 mins ago
Stocks recovered from an early sell-off to end higher Tuesday on expectations the Federal Reserve will maintain its dovish stance on interest rates. The Nasdaq and the S&P 500 both rallied 0.7%, while the Dow Jones industrial average rose 0.6%....
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 52 mins ago
Synthetic Biologics (SYN) announced that the FDA has granted orphan drug designation to its SYN-005.
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:45PM CDT
Gild (GILD) inked deals to make generic Sovaldi available to developing nations.
Glimcher and Apple are big market movers
AP - Tue Sep 16, 3:44PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Gilead Up As Analyst Lifts Sovaldi Q3 Estimate
at Investor's Business Daily - Tue Sep 16, 12:57PM CDT
Gilead Sciences (GILD) stock was rebounding in afternoon trading on the stock market today, as an analyst lifted his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. FBR analyst Andrew Berens raised his estimate to $2.24 billion from...
Midday Glance: Biotechnology companies
AP - Tue Sep 16, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 16, 9:43AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J, Merck & Vertex Pharmaceuticals
M2 - Tue Sep 16, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rlbk3z/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow at a CAGR of 19.2% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies. According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy. Further, the report states that the side effects of current therapies are one of the major challenges in the market. Currently, approved drugs for hepatitis C are associated with poor tolerability and lower patient compliance rates. This, in turn, decreases the market revenue of the currently approved drugs. Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Johnson & Johnson - Merck - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Key Marketed Drugs for Treatment of Chronic Hepatitis C - Market Segmentation by MOA - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rl..._hepatitis
Stock Futures Mildly Lower; Netflix, Gilead Still Sliding
at Investor's Business Daily - Tue Sep 16, 8:09AM CDT
Stock futures sifted deeper ahead of the open in a quiet premarket session Tuesday. Dow futures were down 27.1 points. Nasdaq 100 futures were off 6.6 points, and S&P 500 futures slipped 1.9 points. The stock market today opens with both the Nasdaq...
Market Maker Surveillance Report. BAC, GILD, EMC, S, NIHD, MJNA, Highest Net Sell Volume and Negative Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Monday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. BANK OF AMERICA CORPORATION (NYSE:BAC), GILEAD SCIENCES, INC. (NASDAQ:GILD), EMC Corp (NYSE:EMC), Sprint Nextel Corp (NYSE:S), NII Holdings Inc (NASDAQ:NIHD), Medical Marijuana Inc (OTC:MJNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
Final Glance: Biotechnology companies
AP - 6 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Gilead Sciences
at Investor's Business Daily - 59 mins ago
Gilead Sciences (GILD) shares rose 3.7% to 104.76, as FBR analyst Andrew Berens raised his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. Berens raised his estimate to $2.24 bil from $1.94 bil after examining Aug. prescription data...
AHF Joins National Coalition on Health Care's 'Campaign for Sustainable Rx Pricing'
Business Wire - 1 hr 31 mins ago
--The Bay Area drug company drew outrage--and Congressional scrutiny--by pricing its hepatitis C drug Sovaldi at $84,000 for a 12-week course of treatment--or $1,000 per pill. Pharmasset, the company that developed Sovaldi--and for which Gilead paid $11 billion cash--intended to price the drug at $36,000.
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 42 mins ago
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C
Marketwire Canada - 2 hrs 1 min ago
Hetero Group, today announced that it has obtained licensing rights to manufacture and market sofosbuvir and combination drug ledipasvir/sofosbuvir upon approval from Gilead Sciences Inc., USA for 90 countries. Under the said agreement, Hetero is entitled to manufacture and market sofosbuvir and ledipasvir/sofosbuvir in the territories of India, Asia Pacific, Sub-Saharan Africa and other Least Developed Countries. This will expand access of affordable medicines to patients who are infected with chronic hepatitis C in various developing countries. This licensing association marks a significant milestone in ensuring the medicines are accessible globally and thereby addressing the significant public health care issue.
AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 32 mins ago
AstraZeneca (AZN) has entered into an agreement with Eli Lilly and Company (LLY) for the development and commercialization of AZD3293.
Stocks Rise Ahead Of Fed, Led By Biotech, Chip Names
at Investor's Business Daily - 2 hrs 51 mins ago
Stocks recovered from an early sell-off to end higher Tuesday on expectations the Federal Reserve will maintain its dovish stance on interest rates. The Nasdaq and the S&P 500 both rallied 0.7%, while the Dow Jones industrial average rose 0.6%....
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 52 mins ago
Synthetic Biologics (SYN) announced that the FDA has granted orphan drug designation to its SYN-005.
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:45PM CDT
Gild (GILD) inked deals to make generic Sovaldi available to developing nations.
Glimcher and Apple are big market movers
AP - Tue Sep 16, 3:44PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
Gilead Up As Analyst Lifts Sovaldi Q3 Estimate
at Investor's Business Daily - Tue Sep 16, 12:57PM CDT
Gilead Sciences (GILD) stock was rebounding in afternoon trading on the stock market today, as an analyst lifted his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. FBR analyst Andrew Berens raised his estimate to $2.24 billion from...
Midday Glance: Biotechnology companies
AP - Tue Sep 16, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Sep 16, 9:43AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J, Merck & Vertex Pharmaceuticals
M2 - Tue Sep 16, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rlbk3z/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow at a CAGR of 19.2% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies. According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy. Further, the report states that the side effects of current therapies are one of the major challenges in the market. Currently, approved drugs for hepatitis C are associated with poor tolerability and lower patient compliance rates. This, in turn, decreases the market revenue of the currently approved drugs. Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Johnson & Johnson - Merck - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Key Marketed Drugs for Treatment of Chronic Hepatitis C - Market Segmentation by MOA - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rl..._hepatitis
Stock Futures Mildly Lower; Netflix, Gilead Still Sliding
at Investor's Business Daily - Tue Sep 16, 8:09AM CDT
Stock futures sifted deeper ahead of the open in a quiet premarket session Tuesday. Dow futures were down 27.1 points. Nasdaq 100 futures were off 6.6 points, and S&P 500 futures slipped 1.9 points. The stock market today opens with both the Nasdaq...
Market Maker Surveillance Report. BAC, GILD, EMC, S, NIHD, MJNA, Highest Net Sell Volume and Negative Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Monday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. BANK OF AMERICA CORPORATION (NYSE:BAC), GILEAD SCIENCES, INC. (NASDAQ:GILD), EMC Corp (NYSE:EMC), Sprint Nextel Corp (NYSE:S), NII Holdings Inc (NASDAQ:NIHD), Medical Marijuana Inc (OTC:MJNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
